Our clinical studies in adjuvant and neoadjuvant breast cancer cohorts showed that CDK12 overexpression predicts poor vs. more favorable disease course in patients treated with TaxAC vs. CMF, respectively. The gene discussed is CDK12; the disease is breast carcinoma.